CD344抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD344 mouse mAb (green) and negative control (red).    

  
  

CD344 antibody targets the CD344 antigen, also known as Frizzled-5 (FZD5), a member of the Frizzled family of transmembrane receptors. These receptors play a critical role in the Wnt signaling pathway, which regulates key biological processes such as embryonic development, tissue homeostasis, and stem cell maintenance. CD344 (FZD5) specifically binds to Wnt ligands, initiating both canonical (β-catenin-dependent) and non-canonical signaling cascades. Dysregulation of FZD5 is implicated in various cancers, including colorectal, breast, and pancreatic cancers, where it often promotes tumor growth, metastasis, and drug resistance.

CD344 antibodies are widely used in research to study FZD5 expression patterns, signaling mechanisms, and its role in disease. They are essential tools for immunohistochemistry (IHC), Western blotting (WB), and flow cytometry, aiding in the identification of FZD5 in tissues or cell lines. Additionally, these antibodies have therapeutic potential, as blocking FZD5-mediated Wnt signaling may inhibit oncogenic pathways. Some antibody clones (e.g., monoclonal antibodies like 6F10 or 5E6) are validated for specificity and functionality in preclinical models.

The development of CD344 antibodies reflects the growing interest in targeting Wnt-related pathways for cancer therapy and regenerative medicine. However, challenges remain, including optimizing antibody selectivity and minimizing off-target effects. Ongoing research continues to explore their diagnostic, prognostic, and therapeutic applications in precision medicine.